Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound ...

We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we ...

Politically conservative “pro-family” groups ended 2024 by calling to stamp out the “transgender cult,” opposing ...

Of course, product launches were another hot topic in the top 10. Kenvue landed two stories there: Tylenol’s “Easy to Swallow” brand extension at no. 5, and Versalie, which provides virtual menopause ...

The drugmaker launched a campaign supporting its weight loss medication Contrave, all backed by a cover version of Lesley Gore’s 1963 hit “You Don’t Own Me.” ...

Advertisement Article continues below this ad Semiconductor giant Nvidia ... Eli Lilly rose 3.7% after announcing that ...

US regulators on Friday approved the first drug treatment for sleep apnea, permitting the use of a weight-loss medication for ...

To accomplish these goals, it's fair to assume that some people will ultimately turn to weight-loss drugs such as Ozempic and ...

Zepbound is a medication containing tirzepatide ... weight loss has swept through the nation, with eye-catching ads popping up on television and flooding social media platforms.

Advertisement Article continues below this ad Zepbound is FDA-approved to treat obesity and Mounjaro is approved for diabetes ...

Health News // 1 week ago FDA approves weight-loss drug Zepbound to treat sleep apnea Dec. 21 (UPI) -- Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food ...